vimarsana.com

Page 159 - புனே அடிப்படையிலானது சீரம் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oxford COVID-19 vaccine Covishield gets expert panel s nod in India

Oxford COVID-19 vaccine Covishield gets expert panel s nod in India The Serum Institute of India, the world s largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield . Share Via Email   |  A+A A- SII had applied to the Drugs Controller General of India (DCGI) for EUA for Oxford COVID-19 vaccine on December 6. (Representational Photo | AP) By Online Desk An expert panel on COVID-19 from the Central Drugs Standard Control Organisation (CDSCO) has approved the emergency use of the Oxford vaccine Covishield in the country on Friday. The vaccine is being manufactured by Pune-based Serum Institute of India (SII). The official confirmation of the approval from the government however is yet to follow.

Only 30 crore people to be vaccinated, not the entire population: COVID-19 task force head Dr Vinod Paul

: Friday, January 1, 2021, 7:39 PM IST Govt will bear cost of vaccinating 30 crore individuals, not the entire population: COVID-19 task force head Dr Vinod Paul The Central government has finally approved emergency use authorisation of the Oxford-AstraZeneca s coronavirus vaccine Covishield . Only 30 crore people to be vaccinated, not the entire population: COVID-19 task force head Dr Vinod Paul Photo Credit: PTI India s COVID-19 task force head and NITI Aayog member, Dr Vinod Paul, on Friday said that the government with bear the cost of vaccinating 300 million (30 crore) individuals. These individuals will be from the priority groups as identified by the government and not the entire population. Notably, frontline workers, healthcare workers and the elderly will be among those targeted in the initial phase of vaccination.

COVID-19 Vaccine: No approval for Covaxin, expert panel seeks more data from Bharat Biotech

COVID-19 Vaccine: No approval for Covaxin, expert panel seeks more data from Bharat Biotech The meeting comes a day before dry run of the vaccine is slated to commence in all the states and Union Territories to equip the administration. A doctor displays the application of Covaxin in Tezpur, Assam. (Photo: PTI) Share Updated: Jan 1, 2021, 10:19 PM IST The Subject Expert Committee of the Central Drug Standard Control Organisation on Friday has held that the data provided by Bharat Biotech for its coronavirus vaccine ‘Covaxin’ is not sufficient for grant of emergency use approval and has asked for more information, top sources informed news agency IANS.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.